Abstract
Various immunization assays were used to demonstrate the lack of immunogenicity of three BALB/c tumours of spontaneous origin and of a fourth one resulting from foreign body tumorigenesis. All four tumours inhibited the growth of a second implant of the same tumour into the contralateral flank. In our tumour models “concomitant immunity” (1) was not mediated by macrophage or T-cell dependent immune reactions: both thymectomized BALB/c and nude mice (treated or untreated with silica) gave the same results as intact mice; (2) showed some degree of non-specificity, inhibiting the growth of a different tumour in 3/4 cases; though, the existence of a specific component could not be discarded; (3) was proportional to the volume of the primary tumour at the time of the second challenge; (4) was dependent on actively growing primary tumour, not being obtained with progressively increasing daily inocula of irradiated tumour cells; (5) was detectable in an actively growing secondary tumour; recurrent growth after partial surgical excision was inhibited and (6) involved cytostasis of the secondary tumour: a syngeneic graft of the overlying skin led to tumour growth while histological studies revealed the presence of viable tumour cells. It is postulated that “concomitant immunity” or resistance can be generated without the active participation of the immune system and that tumour-related factors are, in certain cases, responsible for blocking the growth of secondary tumours.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Ruggiero, R., Bustuoabad, O., Bonfil, R. et al. “Concomitant immunity” in murine tumours of non-detectable immunogenicity. Br J Cancer 51, 37–48 (1985). https://doi.org/10.1038/bjc.1985.6
Issue Date:
DOI: https://doi.org/10.1038/bjc.1985.6
This article is cited by
-
Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
BMC Cancer (2022)
-
The immune system in cancer metastasis: friend or foe?
Journal for ImmunoTherapy of Cancer (2017)
-
Primary melanoma tumor inhibits metastasis through alterations in systemic hemostasis
Journal of Molecular Medicine (2016)
-
Biphasic effect of a primary tumor on the growth of secondary tumor implants
Journal of Cancer Research and Clinical Oncology (2010)
-
Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors
Cancer Immunology, Immunotherapy (2008)